Navigation Links
Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
Date:6/28/2010

JERUSALEM, June 28, 2010 /PRNewswire-FirstCall/ --

- Results of First Exposure of Type I Diabetes Patients to Oramed's Oral Insulin and of a First-in-Humans Study With its Oral GLP-1 Analog

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that its executive management is participating in the 2010 Scientific Sessions of the American Diabetes Association currently being held in Orlando, Florida. Dr. Miriam Kidron, Chief Scientific Officer, is scheduled to present results of two of the company's recently completed clinical trials between 12:00 - 2:00 PM ET on Monday, June 28, 2010 in Poster Hall C at the Orange County Convention Center.

One presentation will provide an overview of the results of a Phase IIa study testing the company's flagship ORMD-0801 oral insulin capsule in Type I diabetes patients when administered just before (10-90 minutes) a standard meal. This first exposure of Oramed's oral insulin established the drug's safety and efficacy in Type I diabetics. ORMD-0801 led to a significant increase in insulin levels in 61% of the treatment sessions, irrespective of the time lapse between ORMD-0801 administration and mealtime. The oral insulin preparation effectively kept glucose levels in check in all sessions. These data suggest both tolerance of Oramed's platform to preprandial dosing regimens and its therapeutic potential in regulating Type I diabetes.

In addition, Dr. Kidron will present a summary of Oramed's first-in-humans clinical trial testing the safety and efficacy of ORMD-0901, an encapsulated oral GLP-1 analog formulation. The study monitored t
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Life Line Screening ... services announced today the creation of a unique partnership ... MCM is a population health management ... growing list of clients. These important expanded services will ... conditions earlier. Effective prevention reduces cost of care when ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... CITY , May 22, 2013 ... today announced it received 510(k) clearance from the ... diagnostic X-ray image processing workstation that combines radio ... one platform.  Varian,s Nexus DRF Digital X-Ray Imaging ... variety of image receptors, including CCD cameras and ...
Breaking Medicine Technology:Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2
... In a randomized, double-blind, placebo-controlled trial of 247 patients who ... and liver enzymes; however, vitamin E was more successful for ... associated with fatty liver disease, insulin resistance, and obesity, and ... have NASH. The disease progresses to inflammation in the liver ...
... (Nasdaq: GPRO ) announced today that the Company will ... York on November 3, 2009 at approximately 2:10 p.m. Eastern ... Conference in New York on November 18, 2009 at approximately ... be webcast live and may be accessed through a link ...
Cached Medicine Technology:Vitamin E Improves NASH 2Gen-Probe to Webcast Two Upcoming Investor Presentations 2
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 Jury ... nation’s first trial involving a da Vinci lawsuit, ... case, the family of a man who allegedly died of ... more than $8 million in damages from Intuitive Surgical, Inc. ... its physician training program for the da Vinci Surgical System ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...
(Date:5/22/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution plans and health reimbursement ... in 2014 as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:5/22/2013)... may be reaping enormous income for patients whose ... contracted in their intensive care units. , In ... American Journal of Medical Quality , the ... an avoidable central line-associated bloodstream infection (CLABSI) costs ... a similar infection-free patient. Moreover, hospitals earn nearly ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4
... Daniel D. Von Hoff, Physician-in-Chief for the Translational Genomics Research ... Society of Clinical Oncology (ASCO) for his cancer research. ... A. Karnofsky Memorial Award and Lecture at ASCO,s 46th Annual ... ASCO will present the award to Dr. Von Hoff "for ...
... B for those with scent-robbing viral infection, study found ... help people who lose their sense of smell after ... study, 15 patients with post-viral olfactory dysfunction (PVOD) had ... patients were compared with PVOD patients treated with vitamin ...
... can be lost, treatment can work again , THURSDAY, April ... which certain tumor cells that become resistant to cancer drugs ... lead to new ways to combat drug resistance in cancer ... April 1 in the journal Cell . , Although ...
... medicine specialists), subspecialists, medical students, and allied health ... Medicine 2010, the annual scientific meeting of the ... 24 (Thursday - Saturday), at the Toronto Convention ... devoted to adult medicine and is the second-largest ...
... promise for safely removing large brain tumors from an ... sinus cavities, clinical researchers at the Brain Tumor Center ... University Hospital have found. The findings, to be ... Journal of Neurosurgery and previously published online in ...
... of elderly patients. In many cases, a hip fracture is ... health, setting off a long list of potential complications. ... issue of The Journal of Bone and Joint Surgery ... by the American Society of Anesthesiologists (ASA)-is a leading indicator ...
Cached Medicine News:Health News:TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award 2Health News:Study Suggests How Some Cancers Resist Treatment 2Health News:Study Suggests How Some Cancers Resist Treatment 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 2Health News:All you need to know about adult medicine is at Internal Medicine 2010 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 4Health News:All you need to know about adult medicine is at Internal Medicine 2010 5Health News:All you need to know about adult medicine is at Internal Medicine 2010 6Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 2Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 3Health News:Hip surgery success partially predicted by number of other existing conditions 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: